#United States #Farmville #Amlodipine #Norliqva #CMP Pharma

CMP Pharma's Innovative Reformulation of Norliqva®

In a noteworthy development for pediatric healthcare, CMP Pharma has announced the launch of a new alcohol-free reformulation of Norliqva® (amlodipine) Oral Solution, designed specifically for children aged six and older. This new formulation, which is presented at a concentration of 1 mg/mL, incorporates user-friendly features that not only enhance patient experience but also meet important medical requirements.

Key Features of the New Reformulation

The new Norliqva® oral solution stands out due to several improvements that were implemented based on valuable feedback from healthcare professionals:

• - No Refrigeration Required: Unlike many other liquid medications, this solution does not need refrigeration, significantly simplifying storage for caregivers and families. This change alleviates logistical complications and enhances the solution's accessibility for regular use.
• - No Shaking Needed: User convenience is taken a step further as the solution is ready to use without the need for shaking. This feature ensures that both healthcare providers and patients can administer the medication without additional hassle during critical times.
• - Alcohol-Free Formula: By removing alcohol from the formulation, CMP Pharma has addressed a significant concern for pediatric patient care. The alcohol-free version is especially beneficial for children who may have sensitivities or for whom alcohol should be avoided.

Meeting Pediatric Needs

Norliqva® is primarily indicated for the treatment of hypertension. The new formulation is particularly advantageous for pediatric patients who struggle with dysphagia, or difficulty swallowing tablets. Many young patients face challenges when it comes to taking solid medications, so providing a stable and FDA-approved liquid formulation is a substantial improvement, preventing the inconsistencies often associated with crushing tablets or using compounded solutions.

Brad Barger, Chief Transformation Officer at CMP Pharma, emphasizes the importance of continually refining medications to better serve patients. He stated, "The Norliqva alcohol-free reformulation reflects our dedication to optimizing treatment options for the patient populations we serve. We are providing healthcare professionals, caregivers, and patients with an FDA-approved liquid solution with convenient features such as no requirement for refrigeration or shaking prior to use."

Availability and Contact Information

The new alcohol-free Norliqva® oral solution is now available through standard retail distribution channels. Healthcare providers, caregivers, and patients can obtain more information by contacting CMP Pharma directly at 252-753-7111 or visiting their official website at norliqva.com.

About CMP Pharma, Inc.

CMP Pharma is committed to producing a range of pharmaceutical products tailored to meet niche market needs. Their portfolio includes high-value items like oral liquids and semi-solids, and the company prides itself on addressing the unmet medical needs of a diverse patient population. The team brings decades of expertise in drug development and manufacturing, ensuring that their products maintain safety and efficacy to improve patient quality of life.

Important Safety Information

Just like any medication, Norliqva® comes with its own set of important safety information:
Indications: Norliqva® is approved for treating hypertension in both adults and children over the age of six, aiming to lower blood pressure and reduce the risk of cardiovascular events.
Contraindications: It is crucial to note that Norliqva® should not be administered to patients who have a known sensitivity to amlodipine.
* Adverse Reactions: Common side effects include edema, dizziness, flushing, and palpitations, occurring in a dose-related manner. Other reactions, like fatigue and nausea, while less common, should also be monitored.

Healthcare providers must discuss possible side effects with patients and caregivers, ensuring informed decisions regarding treatment with Norliqva®. For reporting suspected adverse reactions, contact CMP Pharma or the FDA directly.

In conclusion, the introduction of an alcohol-free reformulation of Norliqva® represents a significant step forward in pediatric medicine, addressing not only safety concerns but also the practical needs of patients and caregivers alike.